NKG2D signaling in cancer immunosurveillance

International Journal of Cancer

Volumn 136, Issue 8, 2015, Pages 1741-1750

  López Soto, Alejandro ^a   Huergo Zapico, Leticia ^a   Acebes Huerta, Andrea ^a   Villa Alvarez, Mónica ^a   Gonzalez, Segundo ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

Author keywords

Cancer immunosurveillance; Cancer immunotherapy; MICA B; Nk cells; NKG2D; T cells; ULBPs

Indexed keywords

NATURAL KILLER CELL RECEPTOR NKG2D; LIGAND; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELL AGING; CYTOKINE PRODUCTION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE SEQUENCE; HUMAN; IMMUNE EVASION; IMMUNOSURVEILLANCE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ANIMAL; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; HUMANS; IMMUNOTHERAPY; LIGANDS; MONITORING, IMMUNOLOGIC; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; SIGNAL TRANSDUCTION;

EID: 84922590890     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28775     Document Type: Review

References (154)

1. Burnet M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J 1957;1:841-847.
2. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
4. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-148.
5. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-1570.
6. Vesely MD, Kershaw MH, Schreiber RD, et al. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-271.
7. Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225-274.
8. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008;27:5932-5943.
9. Smyth MJ, Swann J, Cretney E, et al. NKG2D function protects the host from tumor initiation. J Exp Med 2005;202:583-588.
10. Guerra N, Tan YX, Joncker NT, et al. NKG2Ddeficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008;28:571-580.
11. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003;3:781-790.
12. Houchins JP, Yabe T, McSherry C, et al. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med 1991;173:1017-1020.
13. Brown MG, Fulmek S, Matsumoto K, et al. A 2-Mb YAC contig and physical map of the natural killer gene complex on mouse chromosome 6. Genomics 1997;42:16-25.
14. Ho EL, Heusel JW, Brown MG, et al. Murine Nkg2d and Cd94 are clustered within the natural killer complex and are expressed independently in natural killer cells. Proc Natl Acad Sci U S A 1998;95:6320-6325.
15. Vance RE, Tanamachi DM, Hanke T, et al. Cloning of a mouse homolog of CD94 extends the family of C-type lectins on murine natural killer cells. Eur J Immunol 1997;27:3236-3241.
16. Kaiser BK, Barahmand-Pour F, Paulsene W, et al. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J Immunol 2005;174:2878-2884.
17. Lopez-Larrea C, Suarez-Alvarez B, Lopez-Soto A, et al. The NKG2D receptor: sensing stressed cells. Trends Mol Med 2008;14:179-189.
18. Wu J, Song Y, Bakker AB, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999;285:730-732.
19. Upshaw JL, Arneson LN, Schoon RA, et al. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat Immunol 2006;7:524-532.
20. Diefenbach A, Tomasello E, Lucas M, et al. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol 2002;3:1142-1149.
21. Gilfillan S, Ho EL, Cella M, et al. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat Immunol 2002;3:1150-1155.
22. Bryceson YT, March ME, Ljunggren HG, et al. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006;107:159-166.
23. Hayakawa Y, Kelly JM, Westwood JA, et al. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol 2002;169:5377-5381.
24. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002;2:116-126.
25. Groh V, Rhinehart R, Randolph-Habecker J, et al. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001;2:255-260.
26. Jamieson AM, Diefenbach A, McMahon CW, et al. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002;17:19-29.
27. Meresse B, Chen Z, Ciszewski C, et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004;21:357-366.
28. Ehrlich LI, Ogasawara K, Hamerman JA, et al. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD81 T cells. J Immunol 2005;174:1922-1931.
29. Wensveen FM, Lenartic M, Jelencic V, et al. NKG2D induces Mcl-1 expression and mediates survival of CD8 memory T cell precursors via phosphatidylinositol 3-kinase. J Immunol 2013;191:1307-1315.
30. Zloza A, Kohlhapp FJ, Lyons GE, et al. NKG2D signaling on CD8 (1) T cells represses T-bet and rescues CD4-unhelped CD8 (1) T cell memory recall but not effector responses. Nat Med 2012;18:422-428.
31. Chu T, Tyznik AJ, Roepke S, et al. Bystanderactivated memory CD8 T cells control early pathogen load in an innate-like, NKG2Ddependent manner. Cell Rep 2013;3:701-708.
32. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-729.
33. Brady J, Carotta S, Thong RP, et al. The interactions of multiple cytokines control NK cell maturation. J Immunol 2010;185:6679-6688.
34. Castriconi R, Cantoni C, Della Chiesa M, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A 2003;100:4120-4125.
35. Espinoza JL, Takami A, Yoshioka K, et al. Human microRNA-1245 down-regulates the NKG2D receptor in natural killer cells and impairs NKG2D-mediated functions. Haematologica 2012;97:1295-1303.
36. Park YP, Choi SC, Kiesler P, et al. Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the gammac cytokines and TGF-beta1. Blood 2011;118:3019-3027.
37. Maasho K, Opoku-Anane J, Marusina AI, et al. NKG2D is a costimulatory receptor for human naive CD81 T cells. J Immunol 2005;174:4480-4484.
38. Roberts AI, Lee L, Schwarz E, et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol 2001;167:5527-5530.
39. Horng T, Bezbradica JS, Medzhitov R. NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway. Nat Immunol 2007;8:1345-1352.
40. Li P, Morris DL, Willcox BE, et al. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol 2001;2:443-451.
41. McFarland BJ, Strong RK. Thermodynamic analysis of degenerate recognition by the NKG2D immunoreceptor: not induced fit but rigid adaptation. Immunity 2003;19:803-812.
42. Bahram S, Bresnahan M, Geraghty DE, et al. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci U S A 1994;91:6259-6263.
43. Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001;14:123-133.
44. Bacon L, Eagle RA, Meyer M, et al. Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J Immunol 2004;173:1078-1084.
45. Takada A, Yoshida S, Kajikawa M, et al. Two novel NKG2D ligands of the mouse H60 family with differential expression patterns and binding affinities to NKG2D. J Immunol 2008;180:1678-1685.
46. Cerwenka A, Bakker AB, McClanahan T, et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000;12:721-727.
47. Diefenbach A, Jamieson AM, Liu SD, et al. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000;1:119-126.
48. Carayannopoulos LN, Naidenko OV, Fremont DH, et al. Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol 2002;169:4079-4083.
49. Fernandez-Messina L, Ashiru O, Aguera-Gonzalez S, et al. The human NKG2D ligand ULBP2 can be expressed at the cell surface with or without a GPI anchor and both forms can activate NK cells. J Cell Sci 2011;124:321-327.
50. Eleme K, Taner SB, Onfelt B, et al. Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D. J Exp Med 2004;199:1005-1010.
51. Raulet DH, Gasser S, Gowen BG, et al. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013;31:413-441.
52. Steinle A, Li P, Morris DL, et al. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics 2001;53:279-287.
53. Gasser S, Orsulic S, Brown EJ, et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005;436:1186-1190.
54. Textor S, Fiegler N, Arnold A, et al. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res 2011;71:5998-6009.
55. Li H, Lakshmikanth T, Garofalo C, et al. Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle 2011;10:3346-3358.
56. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-913.
57. Xu Y. DNA damage: a trigger of innate immunity but a requirement for adaptive immune homeostasis. Nat Rev Immunol 2006;6:261-270.
58. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-870.
59. Venkataraman GM, Suciu D, Groh V, et al. Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J Immunol 2007;178:961-969.
60. Lopez-Soto A, Quinones-Lombrana A, Lopez-Arbesu R, et al. Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor. J Biol Chem 2006;281:30419-30430.
61. Rodriguez-Rodero S, Gonzalez S, Rodrigo L, et al. Transcriptional regulation of MICA and MICB: a novel polymorphism in MICB promoter alters transcriptional regulation by Sp1. Eur J Immunol 2007;37:1938-1953.
62. Suske G, Bruford E, Philipsen S. Mammalian SP/KLF transcription factors: bring in the family. Genomics 2005;85:551-556.
63. Andresen L, Jensen H, Pedersen MT, et al. Molecular regulation of MHC class I chainrelated protein A expression after HDACinhibitor treatment of Jurkat T cells. J Immunol 2007;179:8235-8242.
64. Lopez-Soto A, Folgueras AR, Seto E, et al. HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene 2009;28:2370-2382.
65. Lopez-Soto A, Huergo-Zapico L, Galvan JA, et al. Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor. J Immunol 2013;190:4408-4419.
66. Groh V, Bahram S, Bauer S, et al. Cell stressregulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A 1996;93:12445-12450.
67. Cam H, Dynlacht BD. Emerging roles for E2F: beyond the G1/S transition and DNA replication. Cancer Cell 2003;3:311-316.
68. Jung H, Hsiung B, Pestal K, et al. RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J Exp Med 2012;209:2409-2422.
69. Nausch N, Florin L, Hartenstein B, et al. Cutting edge: the AP-1 subunit JunB determines NK cell-mediated target cell killing by regulation of the NKG2D-ligand RAE-1epsilon. J Immunol 2006;176:7-11.
70. Krizhanovsky V, Yon M, Dickins RA, et al. Senescence of activated stellate cells limits liver fibrosis. Cell 2008;134:657-667.
71. Iannello A, Thompson TW, Ardolino M, et al. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med 2013;210:2057-2069.
72. Eagle RA, Jafferji I, Barrow AD. Beyond stressed self: evidence for NKG2D ligand expression on healthy cells. Curr Immunol Rev 2009;5:22-34.
73. Cerboni C, Zingoni A, Cippitelli M, et al. Antigenactivated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATRdependent mechanism and become susceptible to autologous NK-cell lysis. Blood 2007;110:606-615.
74. Oppenheim DE, Roberts SJ, Clarke SL, et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2005;6:928-937.
75. Ogasawara K, Hamerman JA, Hsin H, et al. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 2003;18:41-51.
76. Coudert JD, Zimmer J, Tomasello E, et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligandexpressing tumor cells. Blood 2005;106:1711-1717.
77. Coudert JD, Scarpellino L, Gros F, et al. Sustained NKG2D engagement induces crosstolerance of multiple distinct NK cell activation pathways. Blood 2008;111:3571-3578.
78. Andre MC, Sigurdardottir D, Kuttruff S, et al. Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction. Int J Cancer 2012;131:1601-1610.
79. Roda-Navarro P, Vales-Gomez M, Chisholm SE, et al. Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function. Proc Natl Acad Sci U S A 2006;103:11258-11263.
80. McCann FE, Eissmann P, Onfelt B, et al. The activating NKG2D ligand MHC class I-related chain A transfers from target cells to NK cells in a manner that allows functional consequences. J Immunol 2007;178:3418-3426.
81. Joly E, Hudrisier D. What is trogocytosis and what is its purpose? Nat Immunol 2003;4:815.
82. Nakamura K, Nakayama M, Kawano M, et al. Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand. Proc Natl Acad Sci U S A 2013;110:9421-9426.
83. Benitez AC, Dai Z, Mann HH, et al. Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells. Proc Natl Acad Sci U S A 2011;108:4081-4086.
84. El-Gazzar A, Cai X, Reeves RS, et al. Effects on tumor development and metastatic dissemination by the NKG2D lymphocyte receptor expressed on cancer cells. Oncogene 2013, in press. doi: 10.1038/onc.2013.435.
85. Groh V, Wu J, Yee C, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-738.
86. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002;169:4098-4102.
87. Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006;66:2520-2526.
88. Eisele G, Wischhusen J, Mittelbronn M, et al. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain 2006;129:2416-2425.
89. Song H, Kim J, Cosman D, et al. Soluble ULBP suppresses natural killer cell activity via downregulating NKG2D expression. Cell Immunol 2006;239:22-30.
90. Eagle RA, Flack G, Warford A, et al. Cellular expression, trafficking, and function of two isoforms of human ULBP5/RAET1G. PLoS One 2009;4:e4503.
91. Chitadze G, Bhat J, Lettau M, et al. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion, and functional implications. Scand J Immunol 2013;78:120-129.
92. Marten A, von Lilienfeld-Toal M, Buchler MW, et al. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int J Cancer 2006;119:2359-2365.
93. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003;102:1389-1396.
94. Chitadze G, Lettau M, Bhat J, et al. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17. Int J Cancer 2013;133:1557-1566.
95. Liu G, Atteridge CL, Wang X, et al. The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metalloproteinases. J Immunol 2010;184:3346-3350.
96. Kohga K, Takehara T, Tatsumi T, et al. Anticancer chemotherapy inhibits MHC class Irelated chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Cancer Res 2009;69:8050-8057.
97. Sun D, Wang X, Zhang H, et al. MMP9 mediates MICA shedding in human osteosarcomas. Cell Biol Int 2011;35:569-574.
98. Boutet P, Aguera-Gonzalez S, Atkinson S, et al. Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol 2009;182:49-53.
99. Kaiser BK, Yim D, Chow IT, et al. Disulphideisomeraseenabled shedding of tumourassociated NKG2D ligands. Nature 2007;447:482-486.
100. Gumireddy K, Sun F, Klein-Szanto AJ, et al. In vivo selection for metastasis promoting genes in the mouse. Proc Natl Acad Sci U S A 2007;104:6696-6701.
101. Zocchi MR, Catellani S, Canevali P, et al. High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. Blood 2012;119:1479-1489.
102. Huergo-Zapico L, Gonzalez-Rodriguez AP, Contesti J, et al. Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding. Cancer Immunol Immunother 2012;61:1201-1210.
103. Cao W, Xi X, Hao Z, et al. RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2Dmediated NK cytotoxicity. J Biol Chem 2007;282:18922-18928.
104. Bobrie A, Colombo M, Raposo G, et al. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic 2011;12:1659-1668.
105. Fernandez-Messina L, Ashiru O, Boutet P, et al. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J Biol Chem 2010;285:8543-8551.
106. Hedlund M, Nagaeva O, Kargl D, et al. Thermaland oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS One 2011;6:e16899.
107. Clayton A, Mitchell JP, Court J, et al. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 2008;180:7249-7258.
108. Croce CM. Causes and consequences of micro-RNA dysregulation in cancer. Nat Rev Genet 2009;10:704-714.
109. Stern-Ginossar N, Gur C, Biton M, et al. Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol 2008;9:1065-1073.
110. Yadav D, Ngolab J, Lim RS, et al. Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma-induced micro-RNA. J Immunol 2009;182:39-43.
111. Tsukerman P, Stern-Ginossar N, Gur C, et al. MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells. Cancer Res 2012;72:5463-5472.
112. Tang KF, Ren H, Cao J, et al. Decreased Dicer expression elicits DNA damage and upregulation of MICA and MICB. J Cell Biol 2008;182:233-239.
113. Heinemann A, Zhao F, Pechlivanis S, et al. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stressinduced ligand of the natural killer cell receptor NKG2D. Cancer Res 2012;72:460-471.
114. Heinemann A, Paschen A. Tumor suppressors control ULBP2, an innate surface ligand of the lymphocyte immune receptor NKG2D. Oncoimmunology 2012;1:535-536.
115. Nice TJ, Coscoy L, Raulet DH. Posttranslational regulation of the NKG2D ligand Mult1 in response to cell stress. J Exp Med 2009;206:287-298.
116. Nice TJ, Deng W, Coscoy L, et al. Stress-regulated targeting of the NKG2D ligand Mult1 by a membrane-associated RING-CH family E3 ligase. J Immunol 2010;185:5369-5376.
117. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-116.
118. Sers C, Kuner R, Falk CS, et al. Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells. Int J Cancer 2009;125:1626-1639.
119. Armeanu S, Bitzer M, Lauer UM, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005;65:6321-6329.
120. Diermayr S, Himmelreich H, Durovic B, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008;111:1428-1436.
121. Skov S, Pedersen MT, Andresen L, et al. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 2005;65:11136-11145.
122. Tang KF, He CX, Zeng GL, et al. Induction of MHC class I-related chain B (MICB) by 5-aza-20-deoxycytidine. Biochem Biophys Res Commun 2008;370:578-583.
123. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007;7:880-887.
124. Roy S, Barnes PF, Garg A, et al. NK cells lyse T regulatory cells that expand in response to an intracellular pathogen. J Immunol 2008;180:1729-1736.
125. Ghiringhelli F, Menard C, Terme M, et al. CD41CD251 regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005;202:1075-1085.
126. Smyth MJ, Teng MW, Swann J, et al. CD41CD251 T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006;176:1582-1587.
127. Bui JD, Carayannopoulos LN, Lanier LL, et al. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J Immunol 2006;176:905-913.
128. Schwinn N, Vokhminova D, Sucker A, et al. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2Dmediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer 2009;124:1594-1604.
129. Zhang C, Niu J, Zhang J, et al. Opposing effects of interferon-alpha and interferon-gamma on the expression of major histocompatibility complex class I chain-related A in tumors. Cancer Sci 2008;99:1279-1286.
130. Pietra G, Manzini C, Rivara S, et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 2012;72:1407-1415.
131. Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 2010;10:213-221.
132. Ho VT, Vanneman M, Kim H, et al. Biologic activity of irradiated, autologous, GM-CSFsecreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A 2009;106:15825-15830.
133. Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 2012;4:127ps8.
134. Vacchelli E, Eggermont A, Fridman WH, et al. Trial watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013;2:e24238.
135. Vivier E, Ugolini S, Blaise D, et al. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012;12:239-252.
136. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308.
137. Meehan KR, Talebian L, Tosteson TD, et al. Adoptive cellular therapy using cells enriched for NKG2D1CD31CD81T cells after autologous transplantation for myeloma. Biol Blood Marrow Transplant 2013;19:129-137.
138. Spear P, Barber A, Sentman CL. Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. Oncoimmunology 2013;2:e23564.
139. Zhang T, Lemoi BA, Sentman CL. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 2005;106:1544-1551.
140. Barber A, Zhang T, DeMars LR, et al. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res 2007;67:5003-5008.
141. Lehner M, Gotz G, Proff J, et al. Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One 2012;7:e31210.
142. Zhang T, Barber A, Sentman CL. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res 2006;66:5927-5933.
143. Chang YH, Connolly J, Shimasaki N, et al. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res 2013;73:1777-1786.
144. Barber A, Meehan KR, Sentman CL. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Ther 2011;18:509-516.
145. Teng MW, Kershaw MH, Hayakawa Y, et al. T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner. J Biol Chem 2005;280:38235-38241.
146. von Strandmann EP, Hansen HP, Reiners KS, et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006;107:1955-1962.
147. Paschen A, Sucker A, Hill B, et al. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 2009;15:5208-15.
148. Chang YT, Wu CC, Shyr YM, et al. Secretomebased identification of ULBP2 as a novel serum marker for pancreatic cancer detection. PLoS One 2011;6:e20029.
149. Folgueras AR, Pendas AM, Sanchez LM, et al. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004;48:411-424.
150. Fonseca C, Soiffer R, Ho V, et al. Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. Blood 2009;113:1681-1688.
151. Jinushi M, Hodi FS, Dranoff G. Therapyinduced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A 2006;103:9190-9195.
152. Gonzalez S, Lopez-Soto A, Suarez-Alvarez B, et al. NKG2D ligands: key targets of the immune response. Trends Immunol 2008;29:397-403.
153. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5:37-50.
154. Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012;90:85-94.